Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5230MR)

This product GTTS-WQ5230MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5230MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4862MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ10261MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ10891MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ930MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10718MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ595MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ9032MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ438MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 3C23K
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW